| |||||||||||||||||||
| |||||||||||||||||||
See if Relevant | |||||||||||||||||||
Additional Information | It is important for the Blood Services to know that anything being given to a donor as part of a clinical trial will not affect either the safety of the donor or of any potential recipient. If medical staff are given the contact details of the person responsible for the trial any safety issues can be checked.
Some patients with Covid-19 have been enrolled in clinical trials. Many of these trials involve the use of drugs which interact with the immune system. Specific drugs listed in the table above include interferons and other cytokines, monoclonal antibodies (which have generic drug names ending in ‘mab’) and tyrosine kinase inhibitors (which have generic drug names ending in ‘inib’). Because of potential effects on the immune system, donors receiving these types of drug are deferred for a year.
Steroid therapy for treatment of covid-19 is usually a short course of 10 days or less. As donors are deferred for 28 days post recovery from covid-19, they will have already passed the 7 day deferral period for short term systemic steroids.
When a particular drug treatment is being assessed, trial participants are randomly allocated to receive the treatment or a placebo drug. Participants should know which treatment is under investigation in their trial (or trial arm) but will not know whether they have had the treatment or not. They should be assessed for donation on the basis that they might have done.
Some donors may not recall which treatment was under investigation in their trial (or trial arm). In this case, the donor should be asked to find out and contact us again when they have the information available. | ||||||||||||||||||
Reason for change | Removal of the discretion allowing recipients of Covid-19 convalescent plasma to donate convalescent plasma after recovery. |
This entry was last updated in:
DSG-WB Edition 203, Release 60.